| Naslov
|
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial (Article)
|
| Autori
|
Reck Martin ... Andric Zoran G ... (broj koautora 18)
|
| Info |
JOURNAL OF THORACIC ONCOLOGY, (2024), vol. 19 br. 2, str. 297-313
|
| Projekat
|
Healthcare business of Merck KGaA, Darmstadt, Germany; Pfizer |
| Ispravka
|
ISI/Web of Science
Članak
Elečas
Rang časopisa
Citati: |
|
|
